Targeting the Bone Marrow Microenvironment

Michele Moschetta, Yawara Kawano, Klaus Podar

Research output: Contribution to book/report/conference proceedingChapter in book/report

10 Citations (Scopus)


Unprecedented advances in multiple myeloma (MM) therapy during the last 15 years are predominantly based on our increasing understanding of the pathophysiologic role of the bone marrow (BM) microenvironment. Indeed, new treatment paradigms, which incorporate thalidomide, immunomodulatory drugs (IMiDs), and proteasome inhibitors, target the tumor cell as well as its BM microenvironment. Ongoing translational research aims to understand in more detail how disordered BM-niche functions contribute to MM pathogenesis and to identify additional derived targeting agents. One of the most exciting advances in the field of MM treatment is the emergence of immune therapies including elotuzumab, daratumumab, the immune checkpoint inhibitors, Bispecific T-cell engagers (BiTes), and Chimeric antigen receptor (CAR)-T cells. This chapter will review our knowledge on the pathophysiology of the BM microenvironment and discuss derived novel agents that hold promise to further improve outcome in MM.

Original languageEnglish
Title of host publicationPlasma Cell Dyscrasias
Number of pages40
Publication statusPublished - 2016
Externally publishedYes

Publication series

NameCancer Treatment and Research
PublisherSpringer Netherlands
ISSN (Print)0927-3042


  • Animals
  • Bone Marrow/pathology
  • Humans
  • Multiple Myeloma/pathology
  • Tumor Microenvironment


Dive into the research topics of 'Targeting the Bone Marrow Microenvironment'. Together they form a unique fingerprint.

Cite this